NCT04019288 - AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal Carcinoma

Interventions

DRUG

Batiraxcept

Given IV

BIOLOGICAL

Durvalumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston